164 related articles for article (PubMed ID: 29959563)
1. Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.
Hosaka S; Katagiri H; Niwakawa M; Harada H; Wasa J; Murata H; Takahashi M
Int J Clin Oncol; 2018 Dec; 23(6):1127-1133. PubMed ID: 29959563
[TBL] [Abstract][Full Text] [Related]
2. Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma.
Heianna J; Makino W; Ariga T; Ishikawa K; Kusada T; Maemoto H; Toguchi M; Ito J; Goya M; Miyazato M; Iraha Y; Murayama S
Eur Radiol; 2020 Mar; 30(3):1525-1533. PubMed ID: 31728686
[TBL] [Abstract][Full Text] [Related]
3. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
4. [Effect of radiotherapy and bisphosphonate on bone metastases from renal cell carcinoma].
Okuda H; Sugiura H; Yamada K; Hayashi N; Soga N; Ogura Y
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1497-501. PubMed ID: 24231702
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
9. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma.
Harada H; Shikama N; Wada H; Uchida N; Nozaki M; Hayakawa K; Yamada K; Nagakura H; Ogawa H; Miyazawa K; Katagiri H; Nakamura N
Jpn J Clin Oncol; 2021 Jan; 51(1):100-105. PubMed ID: 32869095
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.
Venton G; Ducournau A; Gross E; Lechevallier E; Rochwerger A; Curvale G; Zink JV; Salas S; Deville JL
Anticancer Res; 2012 Feb; 32(2):701-5. PubMed ID: 22287766
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Manoukian GE; Tannir NM; Jonasch E; Qiao W; Haygood TM; Tu SM
Clin Genitourin Cancer; 2011 Dec; 9(2):81-8. PubMed ID: 21958521
[TBL] [Abstract][Full Text] [Related]
14. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
15. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
16. Effect of Bisphosphonates on Skeletal Related Events in Long Bone Metastases of Renal Cell Carcinoma: A Systematic Review.
van Broekhoven DL; Dootjes LW; van der Veldt A; Zillikens C; van Oldenrijk J
Clin Genitourin Cancer; 2023 Jun; 21(3):e190-e197. PubMed ID: 36707394
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of multimodal treatment outcome in renal cell carcinoma patients with bone metastasis].
Mukai S; Tsukino H; Goto T; Sugie S; Shitamura T; Kamimura T; Kamoto T
Hinyokika Kiyo; 2013 Apr; 59(4):207-12. PubMed ID: 23635454
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of brain metastasis of renal cell carcinoma.
Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A
Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008
[TBL] [Abstract][Full Text] [Related]
20. Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases.
Nieder C; Dalhaug A; Pawinski AR
In Vivo; 2020; 34(2):675-678. PubMed ID: 32111768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
